SpyGlass Ophthalmics snags $27.5m Series B
SpyGlass Ophthalmics, an ophthalmic therapeutics company, has secured $27.5 million in Series B financing.
8 January 2021•1 min read
SpyGlass Ophthalmics, an ophthalmic therapeutics company, has secured $27.5 million in Series B financing.
